Best of October 2025: Top 5 Insights In Drug Formulation & Delivery

#1 - Drug Delivery Product Strategy: Aligning The Organization For Execution

In this article, Fran DeGrazio shares best practices for aligning strategic product initiatives with functional area execution. She outlines 5 key considerations, illustrated with the increasingly common market strategy expansion from drug product development to drug-device combination product delivery.

#2 - Effective Supplier Management In Drug Delivery Development With Suttons Creek

In this episode of In Combination, Albana Thorpe and Max Lerman from the technical director team at drug delivery product development consultancy Suttons Creek discuss considerations around supplier relationships in product development for combination products and other delivery devices.

#3 - CMC For Long-Acting Injectables For TB

Long-acting injectables (LAIs) could transform tuberculosis (TB) treatment by improving adherence and reducing drug resistance — but developing them requires solving complex CMC challenges around particle size, sterility, and delivery. Learn how the Gates Medical Research Institute is making this treatment a reality.

#4 - Most Frequently Asked Questions On The Revised EU GMP Annex 1: Volume 3

The revised EU GMP Annex 1 brings major updates for sterile drug manufacturers, emphasizing contamination control strategies, stricter environmental monitoring, and advanced aseptic technologies. Get answers to the most frequently asked questions — including what’s changed, who’s affected, and how to stay compliant.

#5 - The Companion Diagnostic Strategy That Combination Product Leaders Need

As combination products redefine precision medicine, companion diagnostics are becoming just as critical as the therapies they enable — shaping who gets treated, when, and why. Learn how to elevate your diagnostic strategy to match your therapeutic one, streamline regulatory alignment, and accelerate market access.